|D045169||Severe Acute Respiratory Syndrome NIH||0.06|
|D018352||Coronavirus Infections NIH||0.05|
There is one clinical trial.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused mass mortality in the last 3 months that necessitates urgent development of new therapeutical agents. So far there is no effective anti-viral drug to reduce viral load that has critical importance to prevent progress into severe viral pneumonia and systemic hyper inflammation state. This project is to offer a biologic agent based on T cell derived exosomes. This is a novel approach using our proprietary protocols for drug development. This clinical trial is to test the safety and efficacy of this new agent following targeted delivery by metered dose inhaler. The project have received proper approvals from the Turkish Ministry of Health and Erciyes University, Kayseri Turkey. Turk-Patent Application Number: PCT/TR2020/050302
Description: Safety AssessmentMeasure: Adverse reaction (AE) and severe AE (SAE) Time: 28 days
Description: Time to Clinical Recovery (TTCR)Measure: Efficacy Assessment Time: 28 days
Description: Efficacy AssessmentMeasure: The Rate of Recovery Without Mechanical Ventilator Time: 28 days